; and (C) by adding at the end the following: Notification under this subsection shall include full disclosure of the problems resulting in the shortage, the source of the active pharmaceutical ingredient, associated medical devices used for preparation or administration included in the finished dosage form, any alternative sources for the active pharmaceutical ingredient that are known or contacted by manufacturer, information concerning the extent of the shortage, the expected duration of the shortage, the expected impact to distribution and availability in pharmacies, and such other information as the Secretary may require. . (b) Manufacturing reporting Section 506C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c ) is amended by adding at the end the following: (j) Manufacturer reporting Each manufacturer of a drug described in subsection (a) or of any active pharmaceutical ingredient or associated medical devices used for preparation or administration included in the finished dosage form of such a drug, shall report in such manufacturer's annual establishment registration and product listing under subsections (b) and (j) of section 510 the specific facilities in which such drug or ingredient is manufactured and contingency and redundancy plans to help ensure uninterrupted supply of the drug or ingredient. Additional manufacturer reporting requirements under this section shall be maintained by the Secretary in a confidential and internal manner for use by the agency to help ensure continued supply of such drugs. . (c) Consumer notification Not later than one year after the date of enactment of this Act, the Secretary shall develop and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives legislative and regulatory recommendations for consumer notification in the case of a drug shortage, discontinuance, or interruption of the manufacture of a drug described in section 506C(a) of the Federal Food,